National Cancer Institute (NCI): Leukemia, Lymphocytic, Chronic, B-Cell trials

The registry lists 115 Leukemia, Lymphocytic, Chronic, B-Cell studies with National Cancer Institute (NCI) as lead sponsor. 4 are open to participants now and 32 have results posted.

Early Phase 1 1Phase 1 71Phase 2 44Phase 3 6No phase 3(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Rituximab Plus Interleukin-2 in Treating Patients With Hematologic CancerCompletedNCT00010192Phase 1
• Thalidomide With or Without Fludarabine in Treating Patients With Hematologic CancerTerminatedNCT00009984Phase 2
• Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00006473Phase 2
• Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic LeukemiaCompletedNCT00006226Phase 2
• 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell LymphomaTerminatedNCT00005950Phase 2
• Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or LeukemiaTerminatedNCT00005786Not applicable
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or SarcomaCompletedNCT00004241Phase 1
• Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or LymphomaCompletedNCT00003970Phase 1
• Flavopiridol in Treating Patients With Chronic Lymphocytic LeukemiaCompletedNCT00003620Phase 2
• Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced CancerCompletedNCT00003451Phase 1
• Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's DiseaseCompletedNCT00003210Phase 2
• Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's LymphomaCompletedNCT00003204Phase 3
• Bryostatin and Vincristine in B-Cell MalignanciesCompletedNCT00003166Phase 1
• Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's LymphomaCompletedNCT00002745Phase 2
• Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow TransplantsCompletedNCT00001830Phase 1